Healing & Recovery / research dosage / Last reviewed 2026-04-04

Plecanatide Research Dosage: Published Protocol Reference

Plecanatide dosage references vary by route and study context. The database lists Oral: 3 mg, Once daily. These are research-context references, not a universal protocol.

Read the full Plecanatide guide Browse answer pages

Direct Answer

Plecanatide (Trulance) is FDA-approved for chronic idiopathic constipation and IBS with constipation, with Phase 3 RCTs demonstrating consistent efficacy on validated endpoints. As a uroguanylin analog that works locally in the GI tract with minimal systemic absorption, it has an excellent safety profile. For guanylate cyclase-C agonist research and IBS-C/CIC treatment, it is a validated option alongside linaclotide.

Evidence grade
Level A
Research status
FDA Approved
Category
Healing & Recovery
Best for
IBS-C, chronic idiopathic constipation, guanylate cyclase-C agonism research

Research Dosage References

Half-Life

Minimal systemic absorption (acts locally in GI tract; plasma concentrations are below quantifiable levels).

Evidence Limits

Dosage entries are compiled from labels, published studies, and research-context references where available. For Plecanatide, the evidence grade is Level A, and the current research status is FDA Approved.

Safety Signals

Evidence Snapshot

Evidence gradeLevel A
Research statusFDA Approved
Best supported outcomesChronic Idiopathic Constipation Relief (Level A), IBS-C Symptom Improvement (Level A), and Diarrhea (Adverse) (Level A)
Primary citation count3
Last reviewed2026-04-04

Related Guides

How to Cite This Page

ExaminePeptides. "Plecanatide Research Dosage: Published Protocol Reference." Last reviewed 2026-04-04. https://examinepeptides.com/answers/plecanatide-research-dosage/

This static answer page is built for fast indexing and direct citation. It summarizes the matching full evidence review and links back to primary sources where the source database includes them.